With six drugs approved for commercial development, Cambridge-based drugmaker Alnylam Pharmaceuticals Inc. is investing $250 ...

The expansion will add about one-third more active manufacturing space to Alnylam's production facility in Norton, and it is ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts. The ...

Massachusetts Institute of Technology professor Phillip Sharp co-founded Alnylam with several others in 2002. It wasn't Sharp ...

Alnylam Pharmaceuticals faces near-term headwinds from TTR franchise momentum concerns. Click here to read why ALNY stock is ...

A technical analysis of Alnylam stock, explaining the recent correction, and what investors should expect next.

Six firms are set to join the Nasdaq 100 Index as part of its annual reconstitution, the benchmark’s overseer said Friday.

Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) were sinking 9.5% lower as of 11:27 a.m. ET on Thursday after falling as much as 12.6% earlier in the day. The sell-off came after the drugmaker ...

Analyst Ritu Baral of TD Cowen maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), retaining the price target of $282.00. Ritu Baral has given his Buy rating due to a combination of ...

The Nasdaq-100 Index has announced its annual reconstitution, with six new companies being added and six being removed, ...

Lululemon Athletica (LULU) to exit the Nasdaq 100 as part of the gauge's annual shakeup, with Seagate (STX) and five others ...

Cantor Fitzgerald analyst Olivia Brayer initiated coverage with a Hold rating on Alnylam Pharma (ALNY – Research Report) yesterday and set a price target of $165.00. The company’s shares closed ...